Resources to Prepare for CARTICEL Surgery

Genzyme provides patient support services through Carticel Care®, a team dedicated to help you through every step of your CARTICEL knee cartilage repair experience – from biopsy to rehabilitation.

About CARTICEL Care: We're here to help you with scheduling, insurance issues, and education.; Learn more about Carticel Care

CARTICEL Care FAQs: How long does knee cartilage repair treatment take? Will my insurance cover it? Will I need physical therapy?; Get answers to your questions

The CARTICEL Care Team: Read bios about the team members that will support and assist you during your CARTICEL treatment.; Meet the team

Prepare For Surgery: Bring a list of your medications to your doctor, prepare your home, and more.; Read tips and suggestions

: Ready to proceed with CARTICEL? You’re already on the right path.; I'm Ready

Indication

Carticel® (autologous cultured chondrocytes) is an autologous cellular product indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft).

CARTICEL should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown.

CARTICEL is not indicated for the treatment of cartilage damage associated with generalized osteoarthritis.

CARTICEL is not recommended for patients with total meniscectomy unless surgically reconstructed prior to or concurrent with CARTICEL implantation.

Important Safety Information

CARTICEL should not be used in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides or materials of bovine origin.

It should not be used in patients who have previously had cancer in the bones, cartilage, fat or muscle of the treated limb.

Pre-existing conditions, including meniscal tears, joint instability, or malalignment should be assessed and treated prior to or concurrent with CARTICEL implantation.

CARTICEL is not routinely tested for transmissible infectious diseases and may transmit disease to the healthcare provider handling CARTICEL.

Use of CARTICEL in children, patients over age 65, or in joints other than the knee has not yet been assessed.

The occurrence of subsequent surgical procedures (SSPs), primarily arthroscopy, following CARTICEL implantation is common. In the Study of the Treatment of Articular Repair (STAR), forty-nine percent (49%) of patients underwent an SSP on the treated knee, irrespective of their relationship to CARTICEL, during the 4-year follow up. The most common serious adverse events (≥5% of patients), derived from STAR, include arthrofibrosis/joint adhesions, graft overgrowth, chondromalacia or chondrosis, cartilage injury, graft complication, meniscal lesion, graft delamination, and osteoarthritis.

For more information on CARTICEL, please see the Package Insert (PDF).

Paulina Ramirez

Learn More

Paulina Ramirez loves to dance. She smiles, "It’s the way I socialize with my friends. It’s the way I release stress. It’s the way I get energy. It’s the way I enjoy life."

See Paulina in action